NCT00099021View on ClinicalTrials.gov

Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

June 27, 2008

Study Completion Date

June 27, 2008

Conditions
Head and Neck CancerOral Leukoplakia
Interventions
DRUG

pioglitazone hydrochloride

Given PO

Trial Locations (1)

55455

University of Minnesota Medical Center-Fairview, Minneapolis

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00099021 - Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia | Biotech Hunter | Biotech Hunter